Evidence map›Paper›PMID 25983041›Full record

Trial reportInvestigational new drugs2015

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

B J Eigl, S North, E Winquist, D Finch, L Wood, S S Sridhar, J Powers, J Good, M Sharma, J A Squire and 6 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Investigational new drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01075308 (A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01075308 phase2completednot on this map

A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

TypeinterventionalSponsorNCIC Clinical Trials GroupRan2010 to 2015Enrolled32ConditionsProstate CancerArmsHDAC inhibitor SB939
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

B J EiglBC Cancer Agency, Vancouver, BC, Canada, bernie.eigl@bccancer.bc.ca.
S North
E Winquist
D Finch
L Wood
S S Sridhar
J Powers
J Good
M Sharma
J A Squire
J Bazov
T Jamaspishvili
M E Cox
P A Bradbury
E A Eisenhauer
K N Chi
BC Cancer Agency · CAQueen's University · CALondon Health Sciences Centre · CAPrincess Margaret Cancer Centre · CAQueen Elizabeth II Health Sciences Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSB939 is a potent oral inhibitor of class 1, 2, and 4 histone deacetylases (HDACs). These three HDAC classes are highly expressed in castration resistant prostate cancer (CRPC) and associated with poor clinical outcomes. We designed a phase II study of SB939 in men with metastatic CRPC.

methodsPatients received SB939 60 mg on alternate days three times per week for 3 weeks on a 4-week cycle. Primary endpoints were PSA response rate (RR) and progression-free survival (PFS). Secondary endpoints included objective response rate and duration; overall survival; circulating tumor cell (CTC) enumeration and safety. Exploratory correlative studies of the TMPRSS2-ERG fusion and PTEN biomarkers were also performed.

resultsThirty-two patients were enrolled of whom 88 % had received no prior chemotherapy. The median number of SB939 cycles administered was three (range 1-8). Adverse events were generally grade 1-2, with five pts experiencing one or more grade three event. One patient died due to myocardial infarction. A confirmed PSA response was noted in two pts (6 %), lasting 3.0 and 21.6 months. In patients with measurable disease there were no objective responses. Six patients had stable disease lasting 1.7 to 8.0 months. CTC response (from ≥5 at baseline to <5 at 6 or 12 weeks) occurred in 9/14 evaluable patients (64 %).

conclusionAlthough SB939 was tolerable at the dose/schedule given, and showed declines in CTC in the majority of evaluable patients, it did not show sufficient activity based on PSA RR to warrant further study as a single agent in unselected patients with CRPC.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsBenzimidazolesDisease-Free SurvivalHistone Deacetylase InhibitorsHumansKallikreinsMaleMiddle AgedNeoplastic Cells, CirculatingProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseSerine EndopeptidasesTrans-ActivatorsAntineoplastic AgentsBenzimidazolesERG protein, humanHistone Deacetylase InhibitorsKallikreinsKLK3 protein, humanProstate-Specific AntigenPTEN PhosphohydrolasePTEN protein, humanSB939 compoundSerine EndopeptidasesTMPRSS2 protein, humanTrans-ActivatorsTranscriptional Regulator ERG

Identifiers

PMID25983041
OpenAlexW235826207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.